|
| Press Releases |
|
 |
|
| Thursday, March 21, 2019 |
|
|
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease |
| Biogen and Eisai, Co., Ltd. announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia. more info >> |
|
| Tuesday, March 12, 2019 |
|
|
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia |
| Eisai Co., Ltd. and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, L.P. have announced that the U.S. FDA has accepted for review the NDA for lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder. more info >> |
|
| Thursday, March 7, 2019 |
|
|
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan |
| Eisai Co., Ltd. announced today that a marketing authorization application has been submitted in Japan for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for use in the treatment of insomnia disorder. more info >> |
|
| Wednesday, February 27, 2019 |
|
|
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan |
| Eisai Co., Ltd. has entered an agreement to support the international non-governmental organization Association for Aid and Relief, Japan's program to raise awareness of mycetoma in Sudan. more info >> |
|
| Thursday, February 21, 2019 |
|
|
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa |
| AbbVie, a research-based global biopharmaceutical company and Eisai Co., Ltd. announced that they have received approval for an additional indication of HUMIRA (generic name: adalimumab [recombinant]), a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa (HS). more info >> |
|
| Wednesday, February 13, 2019 |
|
|
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy |
| Eisai Co., Ltd. announced today that it has submitted an application to the European Medicines Agency (EMA) for its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) seeking approval for use in pediatric patients with epilepsy. more info >> |
|
| Monday, February 4, 2019 |
|
|
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study |
| Eisai Co., Ltd. and Purdue Pharma L.P. announced a six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder. more info >> |
|
| Wednesday, January 30, 2019 |
|
|
Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa |
| Eisai Co., Ltd. has filed a supplementary new drug application in Japan for its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) seeking approval for use as monotherapy for partial-onset seizures, treatment for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation. more info >> |
|
| Tuesday, January 22, 2019 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time |
| Eisai Co., Ltd. has been listed in the 2019 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
| Friday, January 18, 2019 |
|
|
Eisai's Notification Regarding Results of Voluntary Retirement Program |
| Eisai Co., Ltd. announced today that the application period for the first round of the voluntary retirement program it announced on October 25, 2018, has ended and hereby discloses the results. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The India Market Entry Dilemma: What's Holding Manufacturers Back
Apr 4, 2025 22:08 HKT/SGT
|
|
|
3rd Future Cross Border Payments Summit, Dubai 2025: Trends Shaping the Future of Payments
Apr 4, 2025 21:15 HKT/SGT
|
|
|
CISO Indonesia 2025: Elevating Cybersecurity Strategies for a Resilient Digital Future
Apr 4, 2025 20:50 HKT/SGT
|
|
|
analytica Vietnam 2025 Opens Tomorrow: The Leading Laboratory Exhibition Returns to Vietnam
Apr 4, 2025 20:40 HKT/SGT
|
|
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer 
Apr 4, 2025 19:41 HKT/SGT
|
|
|
Kirin and Hitachi begin joint research on the creation of forest-based carbon credits
Apr 4, 2025 15:56 JST
|
|
|
Asiaray Achieves Net Profit Turnaround of RMB10.4 Million in 2024
Apr 4, 2025 14:39 HKT/SGT
|
|
|
Mitsubishi Corporation Announces Corporate Strategy 2027
Apr 4, 2025 9:04 JST
|
|
|
SMBC and Fujitsu partner towards creation of AI-powered data analytics business
Apr 3, 2025 22:10 JST
|
|
|
Connect Marketplace Hong Kong 2025 Concludes Successfully
Apr 3, 2025 18:29 HKT/SGT
|
|
|
JBM Healthcare Completes Acquisition of 90% Interest in Tin Hee Tong
Apr 3, 2025 17:30 HKT/SGT
|
|
|
Guinean Artist Elie Kamano to Release New Single Exploring Africa's Colonial Past
Apr 3, 2025 17:00 HKT/SGT
|
|
|
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025
Apr 3, 2025 17:00 HKT/SGT
|
|
|
JF SmartInvest Holdings Ltd Announces 2024 Annual Results
Apr 3, 2025 15:59 HKT/SGT
|
|
|
AEON CREDIT SERVICE (ASIA) COMPANY LIMITED FY2024/25 Revenue Up to HK$1,759.3 million with Net Profit of HK$400.5 million
Apr 3, 2025 14:04 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
